Morgan Stanley Catalyst Pharmaceuticals, Inc. Transaction History

Morgan Stanley

$1.35 Trillion
Q3 2024

A detailed history of Morgan Stanley transactions in Catalyst Pharmaceuticals, Inc. stock. As of the latest transaction made, Morgan Stanley holds 1,823,274 shares of CPRX stock, worth $37.6 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

1,823,274

Previous 1,012,679 80.04%

Holding current value

$37.6 Million

Previous $15.7 Million 131.07%

% of portfolio

0.0%

Previous 0.0%

19 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$15.19 - $21.35 $12.3 Million - $17.3 Million	810,595 Added 80.04%	1,823,274 $36.2 Million
Q2 2024 Oct 17, 2024	SELL	$14.68 - $16.92 $11.5 Million - $13.3 Million	-786,177 Reduced 43.7%	1,012,679 $15.7 Million
Q2 2024 Aug 14, 2024	SELL	$14.68 - $16.92 $11.5 Million - $13.3 Million	-786,177 Reduced 43.7%	1,012,679 $15.7 Million
Q1 2024 Oct 17, 2024	BUY	$13.18 - $17.11 $10.4 Million - $13.5 Million	786,177 Added 77.63%	1,798,856 $28.7 Million
Q1 2024 Aug 16, 2024	SELL	$13.18 - $17.11 $2.14 Million - $2.78 Million	-162,683 Reduced 8.29%	1,798,856 $28.7 Million
Q1 2024 May 15, 2024	SELL	$13.18 - $17.11 $2.14 Million - $2.78 Million	-162,683 Reduced 8.29%	1,798,856 $28.7 Million
Q4 2023 Aug 16, 2024	BUY	$11.78 - $17.29 $11.2 Million - $16.4 Million	948,860 Added 93.7%	1,961,539 $33 Million
Q4 2023 Feb 13, 2024	BUY	$11.78 - $17.29 $12.4 Million - $18.1 Million	1,048,444 Added 114.82%	1,961,539 $33 Million
Q3 2023 Nov 15, 2023	BUY	$11.69 - $15.02 $222,425 - $285,785	19,027 Added 2.13%	913,095 $10.7 Million
Q2 2023 Aug 14, 2023	SELL	$11.5 - $18.08 $6.14 Million - $9.66 Million	-534,245 Reduced 37.4%	894,068 $12 Million
Q1 2023 May 15, 2023	SELL	$14.34 - $21.05 $4.43 Million - $6.51 Million	-309,090 Reduced 17.79%	1,428,313 $23.7 Million
Q4 2022 Feb 14, 2023	BUY	$12.25 - $19.5 $2.12 Million - $3.38 Million	173,258 Added 11.08%	1,737,403 $32.3 Million
Q3 2022 Nov 14, 2022	BUY	$7.06 - $15.52 $796,953 - $1.75 Million	112,883 Added 7.78%	1,564,145 $20.1 Million
Q2 2022 Oct 27, 2022	BUY	$6.23 - $8.57 $1.31 Million - $1.8 Million	209,936 Added 16.91%	1,451,262 $10.2 Million
Q2 2022 Aug 15, 2022	BUY	$6.23 - $8.57 $1.31 Million - $1.8 Million	209,936 Added 16.91%	1,451,262 $10.2 Million
Q1 2022 Oct 27, 2022	SELL	$5.31 - $8.31 $1.11 Million - $1.74 Million	-209,936 Reduced 14.47%	1,241,326 $10.3 Million
Q1 2022 May 13, 2022	BUY	$5.31 - $8.31 $5.18 Million - $8.11 Million	976,218 Added 368.23%	1,241,326 $10.3 Million
Q4 2021 Feb 14, 2022	BUY	$5.21 - $7.45 $226,676 - $324,134	43,508 Added 19.63%	265,108 $1.79 Million
Q3 2021 Nov 15, 2021	BUY	$4.85 - $6.04 $1.07 Million - $1.34 Million	221,600 New	221,600 $1.18 Million

Others Institutions Holding CPRX

# of Institutions

326

Shares Held

94.6M

Call Options Held

19.1K

Put Options Held

51.1K

View Full List

About CATALYST PHARMACEUTICALS, INC.

Ticker CPRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 102,820,000
Market Cap $2.12B
Description
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthe...

More about CPRX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.

Account